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Abstract
Introduction: The seven in absentia homolog 2 (SIAH2) protein plays a significant role in the hypoxic response by
regulating the abundance of hypoxia-inducible factor-a; however, its role in breast carcinoma is unclear. We
investigated the frequency and expression pattern of SIAH2 in two independent cohorts of sporadic breast cancers.
Methods: Immunohistochemical evaluation of SIAH2protein expression was conducted in normal breast tissues
and in tissue microarrays comprising ductal carcinoma in situ (DCIS) and a cohort of invasive breast carcinomas.
Correlation analysis was performed between SIAH2 and clinicopathological variables and intrinsic breast cancer
subgroups and validated in a cohort of 293 invasive ductal carcinomas. Promoter methylation, gene copy number
and mRNA expression of SIAH2 were determined in a panel of basal-like tumors and cell lines.
Results: There was a significant increase in nuclear SIAH2 expression from normal breast tissues through to DCIS and
progression to invasive cancers. A significant inverse correlation was apparent between SIAH2 and estrogen receptor and
progesterone receptor and a positive association with tumor grade, HER2, p53 and an intrinsic basal-like subtype. Logistic
regression analysis confirmed the significant positive association between SIAH2 expression and the basal-like phenotype.
No SIAH2 promoter methylation was identified, yet there was a significant correlation between SIAH2 mRNA and gene copy
number. SIAH2-positive tumors were associated with a shorter relapse-free survival in univariate but not multivariate analysis.
Conclusions: SIAH2 expression is upregulated in basal-like breast cancers via copy number changes and/or
transcriptional activation by p53 and is likely to be partly responsible for the enhanced hypoxic drive through
abrogation of the prolyl hydroxylases.
Introduction
Hypoxia in breast cancer has profound effects on tumor
biology that are reflected in a poor prognosis and resis-
tance to both chemotherapy and radiotherapy in patients
[1]. Hypoxia-inducible factor (HIF)-1 is critical to the
hypoxic response, being a transcription factor that,
through binding to hypoxia response elements in the pro-
moters of genes, results in expression of proteins involved
in angiogenesis (vascular endothelial growth factor
(VEGF)), glucose metabolism (glucose transporter 1),
metastasis (chemokine (C-X-C motif) receptor 4 and stro-
mal cell-derived factor-1), cell survival and proliferation.
HIF-1 is a dimer consisting of a constitutively
expressed aryl nuclear translocator or HIF-1b and a
hypoxia-inducible HIF-1a.T h el e v e l so fH I F - 1 a are
tightly regulated by three prolyl hydroxylases. In the pre-
sence of molecular oxygen, these enzymes hydroxylate
the prolyl residues 402 and 564 in the oxygen-dependent
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and recognition by the von Hippel-Lindau protein that
leads to its ubiquitination and degradation via the protea-
some. In contrast, under hypoxia, the prolyl hydroxylases
have limited molecular oxygen and are therefore less
effective, which enables HIF-1a stabilization, transloca-
tion to the nucleus and initiation of gene transcription
that benefits the tumor.
Seven in absentia homolog 2 (SIAH2) is one of a
family of RING domain proteins which act alone or as
components of ubiquitin ligase complexes that target
proteins for proteasomal degradation [2]. Siah proteins
can interact with many intracellular pathways, including
the scaffold proteins, transcriptional repressors and
nuclear receptor corepressors and b-catenin. Siah pro-
teins are also involved in hypoxia signaling via regula-
tion of HIF-1a [3] through the targeted degradation of
prolyl hydroxylases under hypoxic conditions. Indeed,
SIAH2-knockout mice have a delayed and abrogated
response to hypoxic conditions that is mediated through
reduced levels of HIF-1a [3,4]. These data suggest that
Siah proteins may significantly alter HIF signaling
through modulation of the prolyl hydroxylases.
Although the role of HIF has been documented in
breast cancer [5,6], there are no data on the expression
of SIAH2 in this disease. We have therefore investigated
SIAH2 expression in breast cancer in two independent
cohorts. Our aims were to (1) document the pattern
and level of SIAH2 expression in breast cancer, (2) cor-
relate expression with conventional clinicopathological
factors, (3) investigate associations of SIAH2 expression
with intrinsic subtypes of breast cancer and (4) deter-
mine the effect of SIAH2 expression on relapse-free
survival.
Materials and methods
Patients
The flow of patients through the study according to the
Reporting Recommendations for Tumor Marker Prog-
nostic Studies (REMARK) criteria is listed in Supple-
mentary Table 1 in Additional file 1 [7] The first cohort
was derived from the Department of Pathology, Peter
MacCallum Cancer Centre, Melbourne, Australia, and
comprised 120 cases with full clinicopathological charac-
teristics but without survival data. The second cohort
was from the Garvan Institute, Sydney, Australia, and
comprised 293 cases with full clinicopathological charac-
teristics including survival data [7]. In total, 439 invasive
cancers with clinicopathological data and follow-up
were available for study. Of these 439 cases, 61 cases
were excluded because of inadequate tumor tissue on
the array. The final cohort of invasive cancers comprised
378 cases (246 cases with survival data). Eighty cases of
pure ductal carcinoma in situ (DCIS) were obtained
from the John Radcliffe Hospital, Oxford, UK, of which
54 had DCIS on tissue microarrays (TMAs) for staining
and clinical data available. Ten cases of normal postme-
nopausal breast tissues from mammoplasties were also
collected. This study has Ethics Committee approvals
(numbers 00/81, 03/90, 09/36, JRC02.216, HREC SVH
H94/080 and H00/36). All patients had operable breast
carcinomas and were not diagnosed with distant meta-
static disease at the time of presentation. Information
regarding patient characteristics, including age, tumor
size, grade, histology and nodal status were collected
from the clinical and pathological records. The median
age of patients included in this study was 54 years
(range, 24 to 87 years). Ninety-three percent of tumors
were invasive ductal tumors not otherwise specified
type, 3% were invasive lobular carcinomas and 4% were
of other histological types (data were unavailable for two
cases). Median tumor size was 20 mm, and the median
tumor grade was 2. Forty-one percent of patients had
nodal disease. Sixty-nine percent of tumors were estro-
gen receptor (ER)-positive, and 14% were human epider-
mal growth factor receptor 2 (HER2)-positive. Patients
less than 50 years of age with node-positive, ER-negative
tumors or tumors larger than 3 cm received adjuvant
chemotherapy (cyclophosphamide, methotrexate and
5-fluorouracil or adriamycin and cyclophosphamide.
Patients with hormone-responsive tumors who were
more than 50 years of age received 5 years of endocrine
therapy. Patients were followed up for a median period
of 58.1 months. During this time, in the 100 patients
from the invasive cohort, two developed recurrence and
86 deaths were considered breast cancer-related.
Immunohistochemistry
T M A sw e r ec o n s t r u c t e df r o m1 - m md i a m e t e r( i n v a s i v e
cancers) or 2-mm cores (DCIS). Sections of 4-μm thick-
ness were used for immunostaining. TMA sections were
dewaxed, and antigen retrieval was performed in 10 mM
sodium citrate, pH 6, in a pressure cooker for 3 min-
utes. Sections were then treated with 3% H2O2 for
5 minutes to remove endogenous peroxides, washed and
incubated with a SIAH2 antibody (NB110-88113; Novus
Biologicals, Littleton, CO, USA) [9,10] at 1:50 dilution
for 90 minutes at room temperature. The peroxidase-
coupled Mouse ImmPRESS (Vector Laboratories,
Burlingame, CA, USA) detection reagent was then used,
and staining was visualized with diaminobenzidine plus
(DAB+; Dako, Campbellfield,V I C ,A u s t r a l i a ) .S e c t i o n s
were counterstained with hematoxylin to visualize
n u c l e i .T oa n a l y z et h ee x p r e s s i o no fS I A H 2i nb r e a s t
cancer progression, we assessed expression using a com-
bination of both intensity and proportion of cells
e x p r e s s i n gS I A H 2[ 1 0 ]N o r m a lb r e a s te p i t h e l i u m
and tumors were scored for intensity (0 = no staining,
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staining) and the percentage of cells (0 = no cells stain-
ing positive, 1 = <10% cells staining positive, 2 = 10% to
50% cells staining positive, 3 = 51% to 80% cells staining
positive and 4 = >80% cells staining positive) as pre-
viously reported [12]. The scores for intensity and per-
centage of positive tumor cells were added to give a
maximum score of 7. A cutoff of >2 (median value) was
used to define two patient groups of approximately
equal size for subsequent statistical analyses.
ER, HER2, epidermal growth factor receptor (EGFR)
and cytokeratin (CK)5/6 staining were used to classify
tumors into four intrinsic subgroups: the basal group
(ER-negative, HER2-negative, CK5/6-positive and/or
EGFR-positive), the luminal group (ER-positive, HER2-
negative), the HER2 group (HER2-positive) and the
negative (null) group (ER-negative, HER2-negative, CK5/
6-negative and EGFR-negative) [13].
Analysis of SIAH2 Methylation
DNA from a separate series of 60 breast carcinomas
(John Radcliffe Hospital, Oxford, UK) and five normal
breast tissues (Peter MacCallum Cancer Centre, Mel-
bourne, VIC, Australia), comprising all breast cancer
phenotypes (50 ER-positive and 10 ER-negative) (also
see Supplementary Table 2 in Additional file 2), and
DNA was also obtained from the breast cancer cell lines
MCF-10A, MCF-7, BT20, SkBr3, Hs578T, T47D, MDA-
MB-157, MDA-MB-468, MDA-MB-453, MDA-MB-231,
MDA-MB-361, BT483 and ZR75. Bisulfite-modified
(EpiTect Bisulfite kit; Qiagen, Hilden, Germany) DNA
were assessed for SIAH2 methylation using methylation-
sensitive high-resolution melting (MS-HRM) [14]. The
MS-HRM primers for SIAH2 were as follows:
5’-TAGAAGCGGGTGGGTTAGGGTTT-3’ (forward)
and 5’-CTAATACACTCCGCAACCCCC-3’ (reverse)
amplified a region corresponding to GenBank accession
number AC011317.23, nucleotides 105279 to 105409,
which contains 17 CpG islands. A polymerase chain
reaction (PCR) assay was performed in a final volume of
20 μl. The PCR reaction mixture consisted of 1× PCR buf-
fer (Qiagen), 2.5 mM MgCl2,2 0 0μM concentrations of
each deoxyribonucleotide triphosphate, a 200 nM concen-
tration of the forward primer, a 200 nM concentration of
the reverse primer, 5 μM SYTO9 intercalating dye (Invi-
trogen, Mulgrave, VIC, Australia), 0.5 U of HotStarTaq
DNA Polymerase (Qiagen), and 1 μl (theoretical amount
10 ng) of bisulfite-modified DNA. The PCR amplification
was performed with an activation step of 15 minutes at
95°C, followed by 50 cycles of 10 seconds at 95°C, 10 sec-
onds at an annealing temperature of 66°C, 20 seconds at
72°C for extension and one denaturation step of 1 minute
at 97°C. HRM was directly performed after PCR amplifica-
tion. PCR products were denatured at 97°C for 1 minute,
then cooled to 75°C with temperature rising by 0.2°C per
second to 97°C and holding for 1 second after each step-
wise increment. Methylated sequences could be identified
by their increased melting temperature [13]. In each assay,
fully methylated, peripheral blood DNA (unmethylated),
different methylation percentage dilution standards and
nontemplate controls were included as controls and stan-
dards. All assays were performed in duplicate.
Copy number analysis of SIAH2
A previous study analyzed both gene expression and
copy number variation using the Illumina Human-6
BeadArray (Illumina, San Diego, CA, 92121, USA) and
the CNV370 SNP array (Illumina) respectively, in a
cohort of familial tumors [14]. These familial tumors
were known to be breast cancer 1, early onset gene
(BRCA1), BRCA2 or non-BRCA1 and non-BRCA2
tumors, and in this previous study the familial tumors
were classified into one of the breast tumor subtypes:
basal-like, luminal A, luminal B, HER2-positive and
normal-like. These data were used to determine the
expression of SIAH2 and its copy number status in 15
basal-like tumors. The copy number of SIAH2 in each
tumor was inferred from the average logR value of eight
single-nucleotide polymorphisms (SNPs), which were
within the SIAH2 open reading frame (n =3 )o ri nt h e
sequence flanking the gene (n = 5).
Results
SIAH2 expression in normal breast, in situ and invasive
breast carcinomas
SIAH2 expression was identified in the nuclei of occa-
sional cells within the luminal layer of ducts and acini
in normal breast tissues in three of 10 patients (30%).
This expression was usually of mild to moderate inten-
sity, and when stratified using the cutoff used for
the tumors, all were considered negative for SIAH2
(Figure 1A). Expression of SIAH2 was observed in the
nuclei of seven of 54 (13%) DCIS cases. The staining
was generally of a moderate to strong intensity with a
homogeneous distribution (Figures 1B and 1C). There
was a nonsignificant increase in SIAH2 from the transi-
tion of normal to in situ disease (P = 0.13) and a signifi-
cant increase in SIAH2 from in situ to invasive breast
carcinoma (P = 0.0006) (Table 1 and Figures 1D and 2).
Association between SIAH2 protein expression and
clinicopathological characteristics in DCIS
There was no significant correlation between SIAH2
expression and nuclear grade, presence of necrosis, age, ER,
progesterone receptor (PR), EGFR or HER2 (all P > 0.05)
or intrinsic phenotypes in DCIS (P = 0.471) (Supplementary
Table 3 in Additional file 3).
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clinicopathological characteristics and intrinsic subtypes
in invasive cancer
In the primary cohort, there was a significant inverse corre-
lation between SIAH2 protein expression and ER (P <
0.0001), PR (P = 0.011) and a positive association with
tumor grade (P < 0.0001) and intrinsic subtype (P = 0.028),
but there was no association with patient age, tumor size,
lymph node status or HER2 (all P > 0.05) (Supplementary
Table 4 in Additional file 4). In the validation cohort, there
was a significant inverse correlation between SIAH2, ER
(P < 0.0001) and PR (P < 0.0001) and a significant positive
association with tumor grade (P < 0.0001), patient age (P =
0.009), HER2 (P = 0.007) and intrinsic subtype
(P < 0.0001), but not with tumor size or lymph node status
(P > 0.05) (Supplementary Table 5 in Additional file 5).
In the combined cohort, there was a significant inverse
correlation between SIAH2 and ER (P < 0.0001) and PR
(P < 0.0001) and a positive correlation with tumor grade
(P < 0.0001), HER2 (P = 0.007), p53 (P < 0.001) and intrin-
sic subtype (P < 0.0001), but not with patient age, tumor
size or lymph node status (P > 0.05) (Table 2). The signifi-
cant associations between SIAH2 expression grade and
intrinsic subgroups were confirmed in a multivariate analy-
sis of tumor phenotype, age, grade and lymph node status
with the basal-like phenotype being more than five
times more likely to express SIAH2 than luminal tumors
(Table 3) (P = 0.015), which was also observed in the
combined cohort (P =0 . 0 4 2 ) .
Figure 1 Immunohistochemistry of seven in absentia homolog 2 (SIAH2) gene in normal, in situ and invasive breast carcinomas. (A)
Occasional nuclear positivity (arrows) in luminal cells in the terminal duct lobular unit. (B) Moderate to strong staining of SIAH2 in the nucleus
of a small proportion of the cell in a high nuclear grade ductal carcinoma in situ with comedo necrosis. (C) Occasional weak to moderate SIAH2
(arrows) staining in a luminal type ductal carcinoma. (D) Strong SIAH2 staining in all nuclei in this basal-like breast carcinoma.
Table 1 c
2 tests, SIAH2 expression in normal breast, DCIS
and invasive cancers
a
Tissue type Negative, n (%) Positive, n (%) Total, n (%)
Normal 10 (100%) 0 (0%) 10 (100%)
DCIS 47 (87%) 7 (13%) 54 (100%)
Invasive 155 (45%) 194 (55%) 349 (100%)
Total 212 (51%) 201 (49%) 413 (100%)
aSIAH2, seven in absentia homolog 2 gene; DCIS, ductal carcinoma in situ; P <
0.0001.
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To assess whether SIAH2 expression in tumors is
modulated by promoter methylation, CpG islands were
identified in the promoter region of SIAH2, and MS-
HRM primers were designed to cover the CpG-rich area
of the promoter region of SIAH2. Five normal breast
tissues, 60 breast carcinomas and 13 breast cancer cell
lines were screened for methylation of SIAH2, but no
promoter methylation was detected in these cancer cell
lines and samples, as shown by the absence of altered
methylation profiles (Supplementary Figure 1 in Addi-
tional file 6).
Correlation of gene expression and relative copy number
of SIAH2 in basal-like tumors
A cohort of familial tumors, which included 15 basal-
like tumors, was previously analyzed on the basis of
gene expression and copy number analysis [15]. The 15
basal-like tumors showed a significant correlation
between SIAH2 expression and estimated copy number
(r = 0.675, P = 0.003) (Figure 3). Two of the 15 basal-
like tumors showed a copy number gain (copy number
of 3) and a further three of 15 basal-like tumors showed
loss of heterozygosity at this region. In contrast, 15 non-
basal-like tumors (10 luminal A, four luminal B and one
normal-like tumor) did not show any copy number
change in this region.
Relationship between SIAH2 expression and relapse-free
and overall survival
There was no correlation present between SIAH2
expression and overall relapse-free survival in DCIS-only
patients (P = 0.68). Although there was a significantly
shorter relapse-free survival in all patients with invasive
carcinomas stratified by SIAH2 (P =0 . 0 0 2 )( F i g u r e4 ) ,
no significant association with relapse-free survival was
observed in univariate analysis in different breast cancer
intrinsic groups stratified by SIAH2 (data not shown).
There was also no significant association between
SIAH2 in invasive carcinomas of all patients and
relapse-free survival in multivariate analysis (Table 4).
Discussion
Hypoxia is a pivotal driver in breast tumor progression,
leading to transcription of several suites of genes
involved in angiogenesis, cell survival, cell proliferation
and an enhanced metastatic phenotype that are advanta-
geous to the neoplastic cells [1]. SIAH2 is part of the
ubiquitin ligase complex that target proteins for protea-
somal degradation and enhances HIF-1a expression by
reducing the abundance of the prolyl hydroxylases
[16,17]. These enzymes, in the absence of SIAH2, hydro-
xylate prolyl residues in the oxygen-dependent domain
of HIF-1a, resulting in HIF-1a proteasomal degradation
and attenuation of the hypoxic response. Since SIAH2
has the potential to profoundly influence the hypoxic
response, we investigated its expression in normal and
neoplastic breast tissues.
We observed significant upregulation of SIAH2 in the
nucleus in the transition from normal to in situ and
invasive carcinomas in breast cancer, supporting the
notion of an important role of SIAH2 in breast cancer
progression. SIAH2 has a nuclear localization signal that
could account for its subcellular pattern of expression
[18]. The increase in SIAH2 in in situ and invasive car-
cinomas correlates with the hypoxia that occurs in neo-
plasia as the metabolic demand of the tumor exceeds
the supply of nutrients and oxygen from the disordered
vasculature that is developing.
Correlation analysis showed a significant relationship
between high levels of breast tumor SIAH2, negative ER
and PR and high HER2. The absence of a positive corre-
lation with ER is of interest, since estrogen has been
reported to induce expression of SIAH2 in ER-positive
breast cancer cell lines [19] and there is a positive rela-
tionship between Siah2 and ER-positive breast tumors
but not the basal-like phenotype in six publicly accessi-
ble data sets [7,20-25] (analysis not shown). This discre-
p a n c yi sl i k e l yd u et ot h ew e l l - d e s c r i b e dd i f f e r e n c e s
between gene expression and protein abundance or to
the fact that ER expression may be heterogeneous in
Figure 2 Semiquantitative seven in absentia homolog 2 (SIAH2)
gene expression in normal, ductal carcinoma in situ (DCIS) and
invasive carcinoma samples.
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Nevertheless, although there was an inverse relationship
between SIAH2 and ER, approximately half of SIAH2-
positive samples expressed ER, suggesting a complex
relationship.
The finding that SIAH2 was significantly associated
with HER2 and basal-like intrinsic breast cancer sub-
types, which for basal-like cancers was confirmed in
multivariate analysis, is in accord with our previous
report of an enhanced hypoxic drive in basal-like can-
cers [26]. In this study, we have demonstrated that
basal-like breast cancers have an intrinsically elevated
SIAH2 level as part of its phenotype that may, partly at
least, explain the mechanism underlying high HIF-1a
expression in this tumor subtype. The upregulation of
SIAH2 may be regulated at several levels. We investi-
gated the potential role that p53 m a yp l a y ,s i n c et h i s
gene is frequently mutated in this tumor type [11]. In
support of this notion is the significant correlation
between SIAH2 and p53 immunostaining. A further
mechanism in basal-like cancer may also involve p38
mitogen-activated protein kinase, which is also upregu-
lated in the basal-like phenotype, as activated p38
increases the activity of SIAH2 [11]. We also explored
the role of SIAH2 promoter methylation to assess
whether protein expression is epigenetically repressed.
We observed no evidence of methylation in any breast
carcinoma cell line, normal breast or in a series of 60
breast cancers of variable phenotypes, making this
mechanism of repression highly unlikely in breast tissues
in either normal tissue or tumoral tissue.
We then hypothesized that since SIAH2 is located on
3q25.1, overexpression might be mediated through gene
amplification. Indeed, this locus is frequently amplified
in basal-like breast cancer [27], and our preliminary
results showed a significant correlation between DNA
Table 2 Contingency table of SIAH2 expression in invasive breast carcinomas of the combined cohort with
clinicopathological parameters
Parameter Negative, N = 169 (45%) Positive, N = 209 (55%) Total, N = 378 (100%) P value
Grade <0.0001
Low 40 (78.4%) 11 (21.6%) 51 (100%)
Intermediate 77 (60.2%) 51 (39.8%) 128 (100%)
High 32 (20.4%) 125 (79.6%) 157 (100%)
Age, yr 0.187
<50 48 (39.3%) 74 (60.7%) 122 (100%)
>50 107 (47.8%) 117 (52.1%) 224 (100%)
Tumor size 0.168
<20 mm 89 (48.6%) 94 (51.4%) 183 (100%)
>20 mm 61 (39.9%) 92 (60.1%) 153 (100%)
Lymph node status 0.915
Negative 83 (45.4%) 100 (54.6%) 147 (100%)
Positive 64 (43.0%) 85 (57.0%) 185 (100%)
ER status <0.0001
Negative 21 (20.8%) 80 (79.2%) 101 (100%)
Positive 129 (54.4%) 108 (45.6%) 237 (100%)
PR status <0.0001
Negative 39 (28.5%) 98 (71.5%) 137 (100%)
Positive 111 (55.2%) 90 (44.8%) 201 (100%)
HER2 status 0.003
Negative 128 (48.3%) 137 (51.7%) 265 (100%)
Positive 22 (29.7%) 52 (70.3%) 74 (100%)
Tumor subtype <0.0001
Luminal 114 (57.6%) 84 (42.4%) 198 (100%)
Basal-like 4 (9.6%) 37 (90.2%) 41 (100%)
Her2 22 (29.3%) 53 (70.7%) 75 (100%)
Null 11 (44%) 14 (56%) 25 (100%)
P53
Negative 108 (57.8%) 79 (42.2%) 187 (100%) <0.001
Positive 12 (18.2%) 54 (81.8%) 66 (100%)
aSIAH2, seven in absentia homolog 2 gene.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
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hypothesis. Specifically, we found that basal-like tumors
showed copy number gain of the SIAH2 locus more fre-
quently than luminal tumors and that basal-like tumors
containing copy number gain were associated with high
expression of SIAH2. Nevertheless, using a more sensi-
tive and specific method for quantifying gene copy num-
ber such as fluorescence in situ hybridization assay,
together with SIAH2 protein expression in a validation
cohort, would be of interest to confirm this finding and
assess whether true amplification occurs.
Although we observed a significantly shorter relapse-
free survival in patients with SIAH2-positive tumors in
univariate analysis, this was not confirmed in the multi-
variate analysis model that included conventional prog-
nostic factors such as tumor size, tumor grade and
lymph node status. While SIAH2 was not an indepen-
dent survival factor in a multivariate analysis model, it
was prognostic in the univariate analysis because of its
strong association with the basal-like phenotype, which
is an independent prognostic factor. Even so, the role of
Table 3 Multivariate analysis in the combined cohort
(N = 378)
Characteristic P value Hazard
ratio
95% CI for hazard
ratios
Tumor type
Luminal
(reference)
0.09
Basal 0.02 4.04 1.3 to 12.8
HER2 0.15 1.64 0.8 to 3.2
Null 0.67 1.23 0.5 to 3.2
Grade
1 0.000
2 0.02 2.61 1.2 to 5.8
3 0.0001 12.72 5.2 to 31.4
Lymph node status 0.28 0.75 0.4 to 1.3
Tumor size >20 mm 0.18 0.69 0.4 to 1.2
Multivariate analysis using a binary logistic regression model of the effect of
SIAH2 expression on tumor subtype (with luminal tumors as a reference),
tumor grade, lymph node status and tumor size.
aaSIAH2, seven in absentia homolog 2 gene.
95% CI, 95% confidence interval; HER2, human epidermal growth factor
receptor 2.
Figure 3 Correlation between seven in absentia homolog 2
(SIAH2) gene copy number changes as assessed by the
average logR array value of eight single-nucleotide
polymorphisms (SNPs) which located in SIAH2 or within the
flanking region of the gene and normalized expression of
SIAH2 in 15 basal-like breast cancers.
Figure 4 Kaplan-Meier curves stratified by seven in absentia
homolog 2 (SIAH2) gene expression for relapse-free survival in
(A) all tumors (N = 246) and (B) luminal tumors (n = 144).
Table 4 Multivariate analysis using the Cox regression
model of relapse-free survival in all breast cancers of
validation cohort (N = 245)
a
Characteristic P value Hazard ratio 95% CI for hazard ratios
SIAH2 0.47 1.24 0.7 to 2.2
Grade
1 (reference) 0.54
2 0.70 0.83 0.3 to 2.1
3 0.70 1.22 0.4 to 3.3
Tumor size 0.12 1.37 0.9 to 2.2
Lymph node status 0.001 2.25 1.4 to 3.7
Tumor type
Luminal 0.004
Basal-like 0.005 3.0 1.4 to 6.4
HER2 0.001 2.9 1.6 to 5.7
Null 0.016 2.5 1.2 to 5.1
aSIAH2, seven in absentia homolog 2 gene.
95% CI, 95% confidence interval, HER2, human epidermal growth factor
receptor 2.
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that patients with SIAH2-positive, ER-positive tumors
have a significantly longer progression-free survival than
patients with SIAH2-negative tumors and also that
Siah2 levels might be a predictive marker of estrogen-
responsive disease [28]. The discrepancy between these
findings and our own are likely due to the use of mRNA
levels to measure SIAH2 by Jansen et al. [28], and,
despite enriching for neoplastic cells, the stromal com-
partment contributed to the overexpression of SIAH2,
thus confounding the comparison. In support of this
notion, it has been shown by expression microarrays
that downregulated SIAH2 in brain metastasis of breast
cancer corresponds with low stromal contamination
[29]. The concept of SIAH2 being a good prognostic
and/or predictive parameter is not in accord with the
role of SIAH2 in regulating the hypoxic response or
with the observation that inhibition of SIAH2 is asso-
ciated with reduced metastases in animal models [30].
SIAH2 appears to have several mechanisms of mediating
its effect. Some SIAH2 substrates bind directly through
an AXVXP motif, some require adaptor proteins and
still others are targeted independently of the above
sequence motif [3]. Thus, depending on the cell context,
SIAH2 is likely to have a variety of effects.
SIAH2 is critical to the level of the hypoxic response
and therefore is a potential target for anticancer therapy.
Indeed, since HIF activation results in the regulation of
a large number of genes, interference with this pathway
would have broad antineoplastic effects in contrast to
targeting individual genes, such as VEGF, with bevacizu-
mab, which is currently used in the clinic. Indeed,
menadione, a specific inhibitor of SIAH2, increased
expression of prolyl hydroxylase with a concomitant
decrease in levels of HIF-1a. This promising therapeutic
approach also retarded the growth of melanoma xeno-
grafts [31]. The potential of this approach has also been
investigated using a short protein fragment that compe-
titively binds to Siah, resulting in reduced breast cancer
growth, which appeared to be mediated through inhibi-
tion of the hypoxic response [4].
Conclusions
In summary, we have shown that in situ and invasive
breast carcinomas upregulate SIAH2 and that it is pre-
ferentially highly expressed in the basal-like subtype,
which can be accounted for in part by increased gene
copy number. High levels of SIAH2 may be partly
responsible for the enhanced hypoxic drive that under-
lies this tumor type, which is chemotherapy- and radio-
therapy-resistant. Targeting SIAH2, the most apical
regulator identified in the hypoxic response pathway,
m a yb eas u i t a b l eo p t i o nf o ra n ticancer therapy in this
breast tumor subtype.
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